Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Androgens for Poor Responders in In Vitro Fertilization

This study has been completed.
Information provided by:
Hospital Clinic of Barcelona Identifier:
First received: June 4, 2008
Last updated: June 5, 2008
Last verified: June 2008
it has been shown that androgens in non human primates may favour follicular growth in the ovaries when animals are treated with gonadotropins which are the hormones used in patients receiving treatment with in vitro fertilization. Therefore, this study investigates the potential usefulness of testosterone treatment preceding gonadotropin administration in in vitro fertilization patients having a previous poor response to gonadotropins alone.

Condition Intervention Phase
Ovarian Response
Drug: Transdermal testosterone
Phase 3

Study Type: Interventional
Official Title: Transdermal Testosterone to Improve Ovarian Response to Gonadotropins in Poor Responder IVF Patients With Normal Basal Concentrations of FSH

Resource links provided by NLM:

Further study details as provided by Hospital Clinic of Barcelona:

Study Start Date: September 2006
Arms Assigned Interventions
Experimental: 1
Transdermal testosterone treatment during the five days preceding gonadotropin therapy in IVF cycles
Drug: Transdermal testosterone
No Intervention: 2


Ages Eligible for Study:   19 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients receiving the second IVF treatment attempt having the first treatment cycle cancelled because of poor ovarian response to gonadotropins

Exclusion Criteria:

  • Previous ovarian surgery
  • Clinical or laboratory profile suggesting premature ovarian failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00693108

Hospital Clinic
Barcelona, Spain, 08036
Sponsors and Collaborators
Hospital Clinic of Barcelona
  More Information

Publications: Identifier: NCT00693108     History of Changes
Other Study ID Numbers: IVFANDROGENS
Study First Received: June 4, 2008
Last Updated: June 5, 2008

Keywords provided by Hospital Clinic of Barcelona:

Additional relevant MeSH terms:
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents processed this record on April 28, 2017